Clinical Trials

Inclusion Criteria:

• Participants aged ≥ 18 years of age or majority, inclusive, with documented diagnosis of MM as per International Myeloma Working Group (IMWG) criteria.
• Participant must have received at least 4 classes of MM treatment (including an IMiD, PI, anti-CD38 mAb, and anti-BCMA therapy), and at least 3 prior LOT.
• Participants must have documented disease progression during or after their last anti-myeloma regimen (as per IMWG).
• Participants must have measurable disease during screening.
• Participant must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Adherence to contraception requirements.

Exclusion Criteria: 

• Participant with known active or history of central nervous system involvement with MM.
• Participant has active systemic fungal, bacterial, viral, or other infection despite appropriate anti-infective treatment at the time of leukapheresis.
• Participant has received any prior therapy directed at GPRC5D or has received other prior treatment for MM without the required washout prior to leukapheresis.
• Participant has inadequate organ function (per protocol definition).

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 2/27/2024. Questions regarding updates should be directed to the study team contact.